407 related articles for article (PubMed ID: 29098927)
1. Radiochemistry and Preclinical PET Imaging of
Gourni E; Del Pozzo L; Bartholomä M; Kiefer Y; T Meyer P; Maecke HR; Holland JP
Mol Imaging; 2017; 16():1536012117737010. PubMed ID: 29098927
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and evaluation of a novel urea-based
Zha Z; Ploessl K; Choi SR; Wu Z; Zhu L; Kung HF
Nucl Med Biol; 2018 Apr; 59():36-47. PubMed ID: 29459281
[TBL] [Abstract][Full Text] [Related]
3. Preclinical Comparative Study of (68)Ga-Labeled DOTA, NOTA, and HBED-CC Chelated Radiotracers for Targeting PSMA.
Ray Banerjee S; Chen Z; Pullambhatla M; Lisok A; Chen J; Mease RC; Pomper MG
Bioconjug Chem; 2016 Jun; 27(6):1447-55. PubMed ID: 27076393
[TBL] [Abstract][Full Text] [Related]
4. 68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging.
Eder M; Schäfer M; Bauder-Wüst U; Hull WE; Wängler C; Mier W; Haberkorn U; Eisenhut M
Bioconjug Chem; 2012 Apr; 23(4):688-97. PubMed ID: 22369515
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and pre-clinical evaluation of a new class of high-affinity
Kelly J; Amor-Coarasa A; Nikolopoulou A; Kim D; Williams C; Ponnala S; Babich JW
Eur J Nucl Med Mol Imaging; 2017 Apr; 44(4):647-661. PubMed ID: 27847991
[TBL] [Abstract][Full Text] [Related]
6. (R)-NODAGA-PSMA: A Versatile Precursor for Radiometal Labeling and Nuclear Imaging of PSMA-Positive Tumors.
Gourni E; Canovas C; Goncalves V; Denat F; Meyer PT; Maecke HR
PLoS One; 2015; 10(12):e0145755. PubMed ID: 26700033
[TBL] [Abstract][Full Text] [Related]
7. Validation of a [Al
Al-Momani E; Israel I; Samnick S
Appl Radiat Isot; 2017 Dec; 130():102-108. PubMed ID: 28950199
[TBL] [Abstract][Full Text] [Related]
8. Development of a Ga-68 labeled PET tracer with short linker for prostate-specific membrane antigen (PSMA) targeting.
Moon SH; Hong MK; Kim YJ; Lee YS; Lee DS; Chung JK; Jeong JM
Bioorg Med Chem; 2018 May; 26(9):2501-2507. PubMed ID: 29655611
[TBL] [Abstract][Full Text] [Related]
9. PSMA-11-Derived Dual-Labeled PSMA Inhibitors for Preoperative PET Imaging and Precise Fluorescence-Guided Surgery of Prostate Cancer.
Baranski AC; Schäfer M; Bauder-Wüst U; Roscher M; Schmidt J; Stenau E; Simpfendörfer T; Teber D; Maier-Hein L; Hadaschik B; Haberkorn U; Eder M; Kopka K
J Nucl Med; 2018 Apr; 59(4):639-645. PubMed ID: 29191856
[TBL] [Abstract][Full Text] [Related]
10. Targeting Prostate-Specific Membrane Antigen (PSMA) with F-18-Labeled Compounds: the Influence of Prosthetic Groups on Tumor Uptake and Clearance Profile.
Bouvet V; Wuest M; Bailey JJ; Bergman C; Janzen N; Valliant JF; Wuest F
Mol Imaging Biol; 2017 Dec; 19(6):923-932. PubMed ID: 28639122
[TBL] [Abstract][Full Text] [Related]
11. Translational Development of a Zr-89-Labeled Inhibitor of Prostate-specific Membrane Antigen for PET Imaging in Prostate Cancer.
Vázquez SM; Endepols H; Fischer T; Tawadros SG; Hohberg M; Zimmermanns B; Dietlein F; Neumaier B; Drzezga A; Dietlein M; Schomäcker K
Mol Imaging Biol; 2022 Feb; 24(1):115-125. PubMed ID: 34370181
[TBL] [Abstract][Full Text] [Related]
12. Improving the Imaging Contrast of
Baranski AC; Schäfer M; Bauder-Wüst U; Wacker A; Schmidt J; Liolios C; Mier W; Haberkorn U; Eisenhut M; Kopka K; Eder M
Bioconjug Chem; 2017 Sep; 28(9):2485-2492. PubMed ID: 28787147
[No Abstract] [Full Text] [Related]
13.
Young JD; Abbate V; Imberti C; Meszaros LK; Ma MT; Terry SYA; Hider RC; Mullen GE; Blower PJ
J Nucl Med; 2017 Aug; 58(8):1270-1277. PubMed ID: 28408532
[TBL] [Abstract][Full Text] [Related]
14. 68Ga-PSMA-HBED-CC PET for Differential Diagnosis of Suggestive Lung Lesions in Patients with Prostate Cancer.
Pyka T; Weirich G; Einspieler I; Maurer T; Theisen J; Hatzichristodoulou G; Schwamborn K; Schwaiger M; Eiber M
J Nucl Med; 2016 Mar; 57(3):367-71. PubMed ID: 26585062
[TBL] [Abstract][Full Text] [Related]
15. [
Janssen JC; Woythal N; Meißner S; Prasad V; Brenner W; Diederichs G; Hamm B; Makowski MR
Mol Imaging Biol; 2017 Dec; 19(6):933-943. PubMed ID: 28707038
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and evaluation of
Choi PS; Lee JY; Park JH; Kim SW
J Labelled Comp Radiopharm; 2018 Jan; 61(1):4-10. PubMed ID: 28901564
[TBL] [Abstract][Full Text] [Related]
17. Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer.
Benešová M; Schäfer M; Bauder-Wüst U; Afshar-Oromieh A; Kratochwil C; Mier W; Haberkorn U; Kopka K; Eder M
J Nucl Med; 2015 Jun; 56(6):914-20. PubMed ID: 25883127
[TBL] [Abstract][Full Text] [Related]
18. Improve the Biodistribution with Bulky and Lipophilic Modification Strategies on Lys-Urea-Glu-Based PSMA-Targeting Radiotracers.
Cai P; Tang S; Xia L; Wang Y; Liu Y; Feng Y; Liu N; Chen Y; Zhou Z
Mol Pharm; 2023 Feb; 20(2):1435-1446. PubMed ID: 36696174
[TBL] [Abstract][Full Text] [Related]
19. In vitro and in vivo evaluation of the bifunctional chelator NODIA-Me in combination with a prostate-specific membrane antigen targeting vector.
Läppchen T; Kiefer Y; Holland JP; Bartholomä MD
Nucl Med Biol; 2018 May; 60():45-54. PubMed ID: 29571066
[TBL] [Abstract][Full Text] [Related]
20. A PSMA Ligand Labeled with Cobalt-55 for PET Imaging of Prostate Cancer.
Dam JH; Olsen BB; Baun C; Høilund-Carlsen PF; Thisgaard H
Mol Imaging Biol; 2017 Dec; 19(6):915-922. PubMed ID: 28924629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]